Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck’s Zontivity Label Isn’t Weighed Down With Safety Language

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA approves antiplatelet inhibitor with a label that makes little mention of the safety concerns seen in lightweight patients, despite a vibrant FDA and advisory panel discussion on how to present the unfavorable data, but the company still has a big marketing challenge ahead.

Advertisement

Related Content

After Statins, Rise Of The Subgroups? IMPROVE-IT Suggests Population Choice Key
Two Psoriasis Therapies Grab CHMP Backing For European Approval
FDA Changed Course On Zontivity Because Of Skepticism Of Subgroups At High Levels
FDA Changed Course On Zontivity Because Of Skepticism Of Subgroups At High Levels
Focus On The Core: Merck Claims R&D Restructuring Poised To Produce Results
FDA Reviewers Say Vorapaxar Approvable, But Question Study Changes
Bleeding Rates In TRA-2P Further Dim Outlook For Merck’s Vorapaxar
Intracranial Hemorrhage The Culprit In Merck's Vorapaxar Trial

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS077303

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel